Eli Lilly (LLY.N) announced on Thursday its acquisition of AtaiBeckley (ATAI.O), joining the race among pharmaceutical companies to develop psychedelic treatments for mental health disorders. The deal, valued at up to $3.8 billion, includes an initial payment of $2.8 billion and additional milestone-based payments of up to $1 billion.
Key Takeaways
Eli Lilly is acquiring AtaiBeckley for up to $3.8 billion, entering the race among pharmaceutical companies to develop psychedelic treatments for mental health disorders. The deal includes an upfront payment of $2.8 billion and potential milestone-based payments of up to $1 billion.
- Eli Lilly acquires AtaiBeckley for up to $3.8 billion
- Deal includes $2.8 billion upfront, with additional $1 billion in milestones
- Acquisition grants access to BPL-003, a psychedelic nasal spray for treatment-resistant depression
- Trump administration's support boosts interest in psychedelic treatments
⚖
▼Source Claims Check
High ConsensusAll 4 publishers report consistent facts across 3 key claims.
| Claim | Status | Reason | |
|---|---|---|---|
| Acquisition Value | Broad Agreement | $3.8 billion deal for AtaiBeckley | |
| Upfront Payment | Broad Agreement | $2.8 billion upfront, $1B in milestones | |
| Bpl-003 Development Stage | Broad Agreement | Phase 3 clinical trials expected in 2029 |
Acquisition Value
Broad Agreement$3.8 billion deal for AtaiBeckley
Upfront Payment
Broad Agreement$2.8 billion upfront, $1B in milestones
Bpl-003 Development Stage
Broad AgreementPhase 3 clinical trials expected in 2029
This analysis is AI-generated and may not perfectly represent each source's reporting. Always read the original articles for full context.
According to Reuters, Lilly will pay $6.75 per AtaiBeckley share in cash, a premium of about 26% over the stock's closing price on Wednesday. As reported by CNBC, this acquisition grants Lilly access to BPL-003, a psychedelic-based nasal spray in late-stage development for treatment-resistant depression.
The interest in psychedelic treatments has been bolstered by U.S. President Donald Trump's directive in April to speed up reviews of certain psychedelic treatments and increase federal funding for research. This deal follows Lilly's recent acquisition of Centessa Pharmaceuticals for up to $7.8 billion, further strengthening its neuroscience portfolio.
As per StatNews.com, the acquisition is part of Lilly's strategy to diversify beyond its cornerstone cardiometabolic franchise. The companies expect the deal to close in the third quarter, marking another significant investment in Lilly's neuroscience pipeline.
How this summary was created
This summary synthesizes reporting from 4 independent publishers using AI. All sources are cited and linked below. NewsBalance is a news aggregator and media literacy tool, not a news publisher. AI-generated content may contain errors or inaccuracies — always verify important information with the original sources.